| Literature DB >> 20451868 |
Michael W Weiner1, Paul S Aisen, Clifford R Jack, William J Jagust, John Q Trojanowski, Leslie Shaw, Andrew J Saykin, John C Morris, Nigel Cairns, Laurel A Beckett, Arthur Toga, Robert Green, Sarah Walter, Holly Soares, Peter Snyder, Eric Siemers, William Potter, Patricia E Cole, Mark Schmidt.
Abstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid beta (Abeta) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Abeta and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD. Copyright 2010. Published by Elsevier Inc.Entities:
Mesh：
Year: 2010 PMID： 20451868 PMCID： PMC2927112 DOI： 10.1016/j.jalz.2010.03.007
Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566